Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue 4, 1996, Pages 179-186

  Kouz, Jalal ^a   Czech, Jörg ^a   Nicolay, Uwe ^a   Dickneite, Gerhard ^a  

^a Behringwerke AG   (Germany)

Author keywords

Coagulation activation; Fibrinogen; Hirudin; Plasma; Platelets; Rabbit study; Recombinant; Tissue factor

Indexed keywords

BLOOD CLOTTING INHIBITOR; FIBRIN MONOMER; FIBRINOGEN; LEPIRUDIN; THROMBOPLASTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; FEMALE; HEMOSTASIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; THROMBOCYTE; THROMBOCYTE COUNT;

ANIMALS; BLOOD COAGULATION; FEMALE; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENTS; HALF-LIFE; HIRUDINS; LEUKOCYTE COUNT; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTHROMBIN TIME; RABBITS; RECOMBINANT PROTEINS; THROMBIN TIME; THROMBOPLASTIN; TIME FACTORS;

EID: 0029842342     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217205     Document Type: Article

References (33)

1. Davie EW, Fujikawa K, Kurachi K, Kisiel W: The role of serine protease in the blood coagulation cascade. Adv Enzymol 1979:48:227-318.
2. Moldow F, Bach RR, Staskus K, Rick PD: Induction of endothelial tissue factor by endotoxin and its precursors. Thromb Haemost 1993; 70:702-706.
3. Conway EM, Bach R, Rosenberg RD. Königsberg WH: Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989:53:231-241.
4. Edgington TS, Mackman N, Ruf W: Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992; 34:S15-S27.
5. Marmur JD, Rossikhina M, Guha A, Fyfe B. Friedrich V. Mendlowitz M, Nemerson Y, Taubman MB: Tissue factor is rapidly induced in arterial smooth muscle after balloon injury'. J Clin Invest 1993:91:2253-2259.
6. Coughlin SR, Vu T-KH, Hung DT, Wheaton VI: Characterization of a functional thrombin receptor: Issues and opportunities. J Clin Invest 1992;89:351-355.
7. Stone ST, Hofsteenge J: Kinetics of inhibition of thrombin by hirudin. Biochemistry 1986:25:4622-4628.
8. Raake W, Kaluser RJ. Elling H, Zeiller P: Antithrombotic action of recombinant hirudin in a venous thrombosis model. Haemostasis 1991;21(suppl 1): 127-132.
9. Walenga JM, Mamdouh B, Mess-more HL, Farced J. Pifarre R: Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg 1991;51:271-277.
10. Nowak G, Markwardt F: Hirudin in disseminated intravascular coagulation. Haemostasis 1991;21:142-148.
11. Markwardt F, Nowak G, Stürzebecher J. Vogel G: Clinico-pharma-cological studies with recombinant hirudin. Thromb Res 1988;52:393-400.
12. Eriksson BI, Kalebo P, Ekman S, Lindbratt S, Kerry R, Close P: Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994;72:227-231.
13. Chesebro JH, Badimon L, Fuster V: Importance of antithrombin therapy during coronary angioplasty. J Am Coll Cardiol 1991; 17:996B-100B.
14. Machovich R, Owen WG: An clas-tasc-dependent pathway of plasminogen activation. Biochemistry 1989: 28:4517-4522.
15. Griessbach U, Sturzebccher J. Markwardt F: Brief communication: Assay of hirudin in plasma using a chromogcnic thrombin substrate. Thromb Res 1985:37:347-350.
16. Dickneitc G, Czech J. Kcupcr H: Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin. Circ Shock 1994;42:183-189.
17. Brockmeier D, Liickel G: Hocrep-PC G. Frankfurt/Main, Internal Report Hoechst AG, 1990.
18. Bauer P: Multiple testing in clinical trials. Stat Med 1991;10:871-890.
19. Bick RL: Disseminated intravascular coagulation. Hematol Oncol Clin North Am 1992;6:1259-1285.
20. Vogel GMT. Meuleman DG, Bour-gondien FGM, Hobbelen PMJ: Comparison of two experimental thrombosis models in rats: Effects of four glycosaminoglycans. Thromb Res 1989;54:399-410.
21. Frcdrich M, Zierz R, Morser J. Wy-dro R, Witt W: A new animal model of venous thrombosis in rats with low flow conditions in the venous blood stream. Blood Coagul Fibrinolysis 1994:5:243-248.
22. Bredbacka S. Blomback M, Wiman B, Pelzer H: Laboratory methods for detecting disseminated intravascular coagulation (DIC): New aspects. Acta Anacsthcsiol Scand 1933;37: 125-130.
23. Nieuwenhuizen W: Soluble fibrin as a molecular marker for a pre-throm-botic state: A mini-review. Blood Coagul Fibrinolysis 1993;4:93-96.
24. Spannagl M, Hoffman H, Siebeck M. Weipert J. Schwarz HP, Schramm W: A purified antithrombin III-hcparin complex as a potent inhibitor of thrombin in porcine endotoxin shock. Thromb Res 1991; 61:1-10.
25. Dickneitc G, Pâques E-P: Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella-pneumoniae-induced sepsis. Thromb Haemost 1993:69:98-102.
26. Kouz J. Czech J. Dickneitc G: Effect of rcc hirudin of tissue factor-induced activation of coagulation in rabbits. Intensive Care Med 1994; 20:53.
27. Bredenberg CE, Taylor GA, Webb WR: The effect of thrombocytopenia on the pulmonary and systemic hemodynamics of canine-endotoxin shock. Surgery 1980;87:59-68.
28. Brendt MC, Phillips DR: Platelet membrane proteins: Composition and receptor function: in Gordon GI (cd): Platelets in Biology and Pathology. Amsterdam, Elsevier/North Holland Biomedical Press. 1981. pp 43-74.
29. Hoffmann A, Markwardt F: Inhibition of the thrombin-platelet reaction by hirudin. Haemostasis 1984; 14:164-169.
30. Jordan RE, Nelson RM. Kolpatrick J. Newgren, Esmon PC, Foumel MA: Inactivation of human antithrombin by neutrophil elastase: Kinetics of the heparin-dependent reaction. J Biol Chcm 1989;264: 10493-10500.
31. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ. Cabot CF, Chesebro JH: Recombinant hirudin in patients with chronic, stable coronary artery disease. Circulation 1993;88:2012-2022.
32. Cardot JMA, Lefèvre GY, Godbil-lon JA: Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration. J Phar-macokinet Biopharm 1994:22:147-156.
33. Agnelli G, Rcnga C, Weitz JI, Nence GG. Hirsh J: Sustained antithrombotic activity of hirudin after its plasma clearance: Comparison with heparin. Blood 1992;80:960-965.